XBI — SPDR(R) S&P(R) Biotech ETF
Data updated: 2026-05-28
XBI — SPDR(R) S&P(R) Biotech ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $7.43B AUM · 0.35% expense ratio · 58.0% 1-yr return. From SEC regulatory filings.
XBI Fund Overview
XBI — SPDR(R) S&P(R) Biotech ETF is a US ETF managed by SPDR Series Trust, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: SPDR Series Trust
- Category: United States Health Care Equity
- Assets under management: $7.43B
- 1-year return: 58.0%
- Ticker: XBI
- SEC CIK: 0001064642
- SEC series ID: S000010018
- Share class ID: C000027706
XBI Holdings
Top 10 holdings of SPDR(R) S&P(R) Biotech ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| State Street Global Advisors | 8.01% |
| Apellis Pharmaceuticals Inc | 1.83% |
| Alkermes PLC | 1.45% |
| Madrigal Pharmaceuticals Inc | 1.38% |
| TG Therapeutics Inc | 1.35% |
| Insmed Inc | 1.34% |
| Scholar Rock Holding Corp | 1.30% |
| Apogee Therapeutics Inc | 1.28% |
| Protagonist Therapeutics Inc | 1.24% |
| Summit Therapeutics Inc | 1.24% |
XBI Portfolio Allocation
Asset-class allocation of SPDR(R) S&P(R) Biotech ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.8% |
| Cash & Equivalents | 8.1% |
| Derivatives | 0.2% |
XBI Performance
Total returns for XBI (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 4.7% |
| 1 year | 58.0% |
| 3 years (annualised) | 19.0% |
| 5 years (annualised) | -1.1% |
XBI Risk Information
Risk metrics for XBI, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 17.4%
XBI Costs and Fees
XBI costs about $35 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.35%
- Gross expense ratio: 0.35%
- Portfolio turnover: 43%
- Brokerage commissions: 0.99 bps of average net assets (SEC N-CEN)
XBI Cashflows
Over the 12 months to 2026-03, SPDR(R) S&P(R) Biotech ETF had net outflows of $375.76M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | −$589.50M |
| 2026-02 | −$443.25M |
| 2026-01 | $307.41M |
| 2025-12 | −$390.06M |
| 2025-11 | $779.38M |
| 2025-10 | $427.72M |
XBI Debt Constituents
No individual debt constituents are reported in SPDR(R) S&P(R) Biotech ETF's latest SEC N-PORT filing.
XBI Prospectus and SEC Filings
Official SPDR(R) S&P(R) Biotech ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.